Improving Hepatocellular Carcinoma Screening

Launched by NAIK VIETTI VIOLI · Apr 12, 2023

Keywords

ClinConnect Summary

This clinical trial is focused on improving the way we detect hepatocellular carcinoma (HCC), a type of liver cancer. Researchers want to find out if using a special type of magnetic resonance imaging (MRI) called abbreviated MRI is better at spotting HCC compared to the usual ultrasound (US) exams that are currently done in clinics. The study will involve patients with chronic liver disease who need regular screening for HCC.

To participate, patients must be adults with chronic liver issues and meet certain criteria set by health guidelines. They should not have a history of liver cancer or other cancers, nor should they have had any major liver procedures like a transplant. Participants will undergo both ultrasound and MRI screenings within the same week, every six months. The goal of the study is to see if the MRI can find liver cancer more effectively than the standard ultrasound method. This research could lead to better early detection of liver cancer, which is crucial for effective treatment.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • All adult patients with chronic liver disease and indication for HCC screening according to the European Association for the Study of the Liver recommendations.
• • Informed Consent signed by the subject
• Exclusion Criteria:
• • History of HCC
• • History of other malignancy
• • Prior liver nodule categorized as LI-RAD 4, 5 or M
• • History of liver transplantation
• • Pregnancy
• • MRI or MRI contrast agent precaution
• • Any other condition making the patient unsuitable for the study
• • Patient's refusal of transmission of relevant medical conditions found on the medical examinations performed during the study